West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. II. Patients without involved axillary lymph nodes
journal contributionposted on 2016-12-14, 16:30 authored by J. M. Morrison, A. Howell, K. A. Kelly, R. J. Grieve, I. J. Monypenny, R. A. Walker, J. A. H. Waterhouse
The aim of this study was to test the effectiveness of a regimen of combination chemotherapy when given as an adjuvant treatment after mastectomy to patients with histologically negative axillary lymph nodes. A total of 574 patients with cancer of the breast and no involvement of axillary lymph nodes were randomised, after simple mastectomy with axillary sampling, to receive either no adjuvant treatment or oral fluorouracil 500 mg, methotrexate 25 mg and chlorambucil 10 mg p.o. on day 1 and fluorouracil 500 mg and chlorambucil 10 mg p.o. on day 2 (LMF) every 21 days for eight cycles. Randomisation was stratified according to menopausal status and tumour size. Treatment was started within 14 days of surgery in 97% of patients. Ninety per cent of patients received eight cycles of chemotherapy with no dose reduction. At a median follow-up of 7 years, there was no evidence that relapse-free or overall survival time were influenced by treatment.
We wish to thank the Cancer Research Campaign for grants to the project, Eli Lilly, Farmitalia Carlo Erba and Lederle for their financial assistance and also the Lions Club International District 105 and the many other groups and individuals within the West Midlands who provided support by fund raising activities or donation. In particular, we thank Lady Veronica Booth for working so hard as patron of our local fund raising campaign.
CitationBritish Journal of Cancer (1989) 60, 919–924.
Author affiliation/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cancer Studies and Molecular Medicine
- VoR (Version of Record)